Smith & Nephew plc (LON: SN)
London
· Delayed Price · Currency is GBP · Price in GBp
1,036.50
+8.50 (0.83%)
Jan 21, 2025, 4:49 PM BST
Smith & Nephew Revenue
Smith & Nephew had revenue of $2.83B USD in the half year ending June 29, 2024, with 8.73% growth. This brings the company's revenue in the last twelve months to $5.64B, up 5.48% year-over-year. In the year 2023, Smith & Nephew had annual revenue of $5.55B with 6.40% growth.
Revenue (ttm)
$5.64B
Revenue Growth
+5.48%
P/S Ratio
2.02
Revenue / Employee
$305.77K
Employees
18,452
Market Cap
9.04B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.55B | 334.00M | 6.40% |
Dec 31, 2022 | 5.22B | 3.00M | 0.06% |
Dec 31, 2021 | 5.21B | 652.00M | 14.30% |
Dec 31, 2020 | 4.56B | -578.00M | -11.25% |
Dec 31, 2019 | 5.14B | 234.00M | 4.77% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Indivior | 881.89M |
Smith & Nephew News
- 4 days ago - Smith & Nephew (SNN) Stock Surges Amid Strong Financial Performance - GuruFocus
- 7 days ago - Smith & Nephew PLC (SNN) Receives Favorable Ratings for Advanced Wound Care Solutions - GuruFocus
- 7 days ago - Smith+Nephew's ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable' Evidence Bar™ ratings from ECRI for pressure injury prevention - GlobeNewsWire
- 7 days ago - Topical Scar Treatment Market to Grow from $1.71 Billion in 2024 to $5.91 Billion by 2035 - Dominated by Smith & Nephew, Molnlycke Health Care, Alliance Pharma, HRA Pharma, and Rejuvaskin - GlobeNewsWire
- 24 days ago - Smith & Nephew chief Deepak Nath in 'last chance saloon' - This is Money
- 4 weeks ago - Smith & Nephew PLC (SNN) Expands CORI Surgical System with FDA-Cleared Hip Arthroplasty Planning - GuruFocus
- 4 weeks ago - Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty - GlobeNewsWire
- 5 weeks ago - Smith & Nephew PLC (SNN) Receives FDA Clearance for AETOS Stemless Shoulder System - GuruFocus